Detalhe da pesquisa
1.
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol
; 22(1): 144-153.e2, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37391056
2.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet
; 399(10342): 2200-2211, 2022 06 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35691323
3.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Clin Gastroenterol Hepatol
; 20(3): 578-590.e4, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33618023
4.
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Gastroenterology
; 157(4): 1019-1031.e7, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31279870
5.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 375(20): 1946-1960, 2016 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-27959607
6.
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Clin Gastroenterol Hepatol
; 17(8): 1525-1532.e1, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30267864
7.
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Gastroenterology
; 154(6): 1660-1671, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29409871
8.
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Gastroenterology
; 155(4): 1045-1058, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29909019
9.
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
J Pharmacokinet Pharmacodyn
; 44(5): 425-436, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28623612
10.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
N Engl J Med
; 367(16): 1519-28, 2012 Oct 18.
Artigo
Inglês
| MEDLINE | ID: mdl-23075178
11.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
J Crohns Colitis
; 2024 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38310565
12.
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Clin Ther
; 44(10): 1336-1355, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36150926
13.
Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis.
Crohns Colitis 360
; 4(3): otac025, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-36777422
14.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
Inflamm Bowel Dis
; 27(7): 994-1007, 2021 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32964215
15.
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
J Crohns Colitis
; 14(1): 23-32, 2020 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31158271
16.
HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients.
Inflamm Bowel Dis
; 2023 Nov 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38029420
17.
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
J Crohns Colitis
; 12(8): 883-895, 2018 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-29726939
18.
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies.
Intest Res
; 15(4): 475-486, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-29142515
19.
An 84-year-old white woman with nausea, vomiting, and abdominal pain.
MedGenMed
; 6(4): 15, 2004 Oct 04.
Artigo
Inglês
| MEDLINE | ID: mdl-15775842
20.
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.
Nat Immunol
; 6(12): 1236-44, 2005 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-16273099